A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)

Summary

This is a phase II single-arm open-label study to investigate the efficacy and safety of volrustomig in women with FIGO 2018 stage IIIA to IVA cervical cancer who have not progressed following platinum-based concurrent chemoradiation therapy (CCRT).

Timeline

Start

2025-03-31

Primary completion

2028-03-13

Completion

2029-03-13

Drugs

Indications